KAHR, today announced publication of preclinical data supporting the development of DSP107, a potential first-in-class investigational CD47x41BB targeting fusion protein designed to activate both the innate and adaptive immune systems, as a monotherapy and in combination for the treatment of cancer.
JERUSALEM, March 15, 2022 /PRNewswire/ -- KAHR, a clinical stage cancer immunotherapy company developing novel dual-targeting protein therapeutics, today announced publication of preclinical data supporting the development of DSP107, a potential first-in-class investigational CD47x41BB targeting fusion protein designed to activate both the innate and adaptive immune systems, as a monotherapy and in combination for the treatment of cancer. The paper, titled “DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity,” was published in the peer-reviewed Journal of Experimental & Clinical Cancer Research and authored by scientists from University Medical Center Groningen (UMCG), headed by Edwin Bremer, Ph.D., Professor at the Department of Hematology/ Immunohematology, University of Groningen, the Netherlands in collaboration with KAHR scientists. The preclinical studies were designed to evaluate the potential for clinical development of DSP107 as monotherapy and in combination with standard of care anti-CD20 monoclonal antibody, rituximab, for Diffuse Large B Cell Lymphoma (DLBCL) patients. In these studies, it was demonstrated that:
“The mainstay of treatment for B Cell non-Hodgkin Lymphoma is chemotherapy combined with rituximab, a CD20 monoclonal antibody,” explained Prof. Bremer. “However, some patients are refractory to this treatment or will develop resistance and relapse with a poor prognosis. We believe our findings provide early support for DSP107’s development as a potential monotherapy and in combination with rituximab for refractory or relapsing DLBCL. DSP107 may have the potential to enable specific and localized activation of both the innate and adaptive immune system against the cancer cells.” Yaron Pereg, Ph.D., Chief Executive Officer of KAHR, added, “We believe this scientific publication provides support for our development of DSP107 as a novel dual-targeting immunotherapy agent for difficult to treat cancers. We are encouraged by the preclinical data that point to a mechanism of action supporting our two clinical programs: the Phase 1b clinical trial of DSP107 in patients with acute myeloid leukemia and myelodysplastic syndrome and the Phase 1/2 study of DSP107 as monotherapy and in combination with an anti-PD-L1 checkpoint inhibitor, in patients with advanced solid tumors.” About DSP107 About KAHR Contacts: Investors Media SOURCE KAHR Medical |